(Q54494748)

English

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Ingolf Cascorbi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

J T Hartmann

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

C Kollmannsberger

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F Mayer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M M Schittenhelm

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Heeger

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

C Bokemeyer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

26 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

661-668

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9856-0

21 January 2018

Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22832803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22832803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22832803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22832803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9856-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22832803%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54494748&oldid=2212487783"